Metaplastic Breast Cancer Global Alliance

Science will never be the same after it got to this point👇and the people making money out of this are not actually contributing to science. More like destruction of science in my opinion. Harvard-affiliated Dana-Farber to pay $15 million to settle US claims over flawed studies apple.news/ASlLV0oDuTIS-S_8J… reuters.com/legal/litigation… Sholto David who is part of the inner circle of PubPeer gets $2.63 million out of this.

🚨BREAKING: Fenbendazole Linked to Remission or Near-Remission in THREE Stage IV Cancer Patients New study reports breast, prostate, and melanoma patients experienced dramatic tumor regression and long-lasting remission — without chemotherapy 👇 ✅Case 1: 83-year-old woman, Stage IV Breast → Complete Remission (3 years) ✅Case 2: 75-year-old man, Stage IV Prostate → Near-Complete Remission (26 months, undetectable PSA) ✅Case 3: 63-year-old man, Stage IV Melanoma → Complete Remission (11 months) Outcomes mirror preclinical findings on fenbendazole’s anti-cancer activity. Similar to ivermectin, fenbendazole may act as a powerful anticancer agent. Clinical trials should be urgently initiated to test fenbendazole’s true potential. Shoutout to @MakisMD for conducting this critically important study.

NEW STUDY: Fenbendazole Linked to Remission or Near-Remission in Three Stage IV Cancer Patients Breast, prostate, and melanoma patients experienced dramatic tumor regression and long-lasting remission — without chemotherapy. The NIH National Cancer Institute should begin large scale multi-center, double-blind randomized trials across a broad array of cancers. @theNCI @McCulloughFund thefocalpoints.com/p/new-stu…

This is a sneak peek at a paper I'm currently writing on Omipalisib, also known as GSK2126458. Last year my lab discovered in roundworms that this dual PI3K/mTOR inhibitor has impressive lifespan-extending effects. In the paper I will share the current findings around the compound and the future steps ahead. One part I’m currently working on is a simplified overview of the main pathways connected to Omipalisib. In this post I’m sharing the first draft of that image which I plan to include in the paper. I would love to get your feedback on it. All feedback is welcome, even the really tough one.

We’re often tempted to believe that diagnosing a recurrence earlier will improve outcomes. Clinical trials, however, suggest the opposite. We need new studies, with new tools (eg ctDNA) & implementation of new treatments. But we also need to inform pts adequately on this topic.

This will be our 2nd year attending. The first was through Patti Hennessy before she passed away. Beautiful venue! Hoping it grows!